Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro-10-9359) Tigason.
In an open trial, eight patients with psoriasis took part in a four-month study to evaluate the effect of a new oral synthetic retinoid Ro-10-9359 (Tigason). All patients improved on the treatment, although one had side effects severe enough to force dosage reduction with less satisfactory control.